Latham & Watkins Advises Pattern Bioscience on US$43 Million Series D Financing

"Latham & Watkins LLP advised Pattern Bioscience on a US$43 million Series D financing led by AMR Action Fund, Illumina Ventures and Omnimed Capital. The funding will support a US multi‑center clinical trial and regulatory submission for the Pneumonia ID/AST Panel, which holds FDA Breakthrough Device Designation and is backed by a BARDA contract up to US$40.9 million."

Latham & Watkins LLP represented Pattern Bioscience in the US$43 million Series D financing. Pattern Bioscience, a leader in rapid diagnostic technologies for bacterial infections, has raised US$43 million in a Series D round led by AMR Action Fund, Illumina Ventures and Omnimed Capital. The proceeds will support completion of a US multi‑center clinical trial and the regulatory submission for the Pneumonia ID/AST Panel, a diagnostic intended for critically ill patients with suspected pneumonia. The Pneumonia ID/AST Panel has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration and is supported by a Biomedical Advanced Research and Development Authority (BARDA) contract valued at up to US$40.9 million. Latham & Watkins LLP represented Pattern Bioscience with a team composed by: partner Scott Craig (Austin/Houston), and associates Kristine LaVeau, Luisa Gomez, and Regan Barney.

Latham & Watkins Advises Pattern Bioscience on US$43 Million Series D Financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads